amlexanox has been researched along with Disease Models, Animal in 6 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Genetic depletion of IKKε or pharmacological inhibition by amlexanox led to a significant reduction of mechanical hyperalgesia and cold allodynia in comparison to control mice." | 3.91 | Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice. ( Fleck, SC; Geisslinger, G; Möller, M; Möser, CV; Niederberger, E; Thomas, D, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) was associated with increased level of lipopolysaccharides (LPS) which mechanism remained unclear on intervention between LPS and NAFLD." | 1.56 | Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling. ( He, Q; Tang, R; Wang, W; Wu, Q; Xia, X; Yao, K; Zeng, J; Zou, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| He, Q | 1 |
| Zeng, J | 1 |
| Yao, K | 1 |
| Wang, W | 1 |
| Wu, Q | 1 |
| Tang, R | 1 |
| Xia, X | 1 |
| Zou, X | 1 |
| Cruz, VH | 1 |
| Arner, EN | 1 |
| Wynne, KW | 1 |
| Scherer, PE | 1 |
| Brekken, RA | 1 |
| Möser, CV | 1 |
| Möller, M | 1 |
| Fleck, SC | 1 |
| Thomas, D | 1 |
| Geisslinger, G | 1 |
| Niederberger, E | 1 |
| Mowers, J | 1 |
| Uhm, M | 1 |
| Reilly, SM | 1 |
| Simon, J | 1 |
| Leto, D | 1 |
| Chiang, SH | 1 |
| Chang, L | 1 |
| Saltiel, AR | 1 |
| Shishikura, T | 1 |
| Shito, K | 1 |
| Uchida, M | 1 |
| Inaba, T | 1 |
6 other studies available for amlexanox and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
Topics: Aminopyridines; Animals; Diet, High-Fat; Disease Models, Animal; Gene Expression; I-kappa B Kinase; | 2020 |
Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Topics: Aminopyridines; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fatty Liver; I-kappa B | 2018 |
Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice.
Topics: Aminopyridines; Animals; Disease Models, Animal; Female; Ganglia, Spinal; Hyperalgesia; I-kappa B Ki | 2019 |
Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Adrenergic beta-3 Receptor Agonists; Aminopyridines | 2013 |
A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs.
Topics: Aminopyridines; Animals; Anti-Allergic Agents; Antigens; Cromolyn Sodium; Cyclosporine; Dinitrobenze | 2006 |